Clinical Trial

Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Evaluate \[18F\]GATT-44 (aka \[18F\]GAT44), to characterize its pharmacokinetic, metabolic, and in vivo binding profile, and assess the reproducibility of kinetic and binding parameters. Assess specific binding levels of \[18F\]GATT-44 by conducting a test-block study in humans. Estimate human dosimetry of \[18F\]GATT-44 by performing whole-body imaging studies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-03.
Trial Details
NCT Number NCT07457736
Lead Sponsor Yale University
Collaborators: National Institute of Mental Health (NIMH)
Conditions Healthy Adult Participants
Enrollment 32 participants
Start Date 2026-04
Primary Completion 2030-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-06